Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2
receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate
the safety and clinical efficacy of a 24-week course of famotidine.